This 1996 review by I.M. Jackson evaluates the evidence supporting the use of thyroid hormones—particularly triiodothyronine (T3)—as adjunctive therapy in depression. The review highlights that hypothyroidism is commonly associated with depressive symptoms and should be treated with levothyroxine (T4). T3 has been shown to accelerate or enhance the response to
This 2013 retrospective longitudinal study analyzed 1,751 individuals with subclinical hypothyroidism and 28,096 euthyroid subjects over a median follow-up of 36 months to assess the impact of seasonal variations on thyroid function. Findings revealed a biphasic pattern in TSH levels, increasing during winter-spring and decreasing in summer-fall. Notably, 57.9% of
This 2012 review by Gary A. Brent in the Journal of Clinical Investigation provides an in-depth exploration of how thyroid hormones (TH), primarily triiodothyronine (T3) and thyroxine (T4), exert their effects through genomic and non-genomic mechanisms. Genomic actions occur via T3 binding to nuclear thyroid hormone receptors (TRα and TRβ),
This review explores the role of various hormone therapies in managing congestive heart failure (CHF). It highlights the significance of neurohormonal systems in CHF pathophysiology and discusses treatments like the dual-acting drug valsartan/sacubitril, which shows promise alongside traditional medications such as beta-blockers, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists. Clinical
